BioSpace News Archive

Doheny Eye Institute has announced that Ronald L. Olson now serves as a member of the DEI Board of Directors after being elected to the position in late 2019.

-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation – -- Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated – -- Pharmacokinetics analysis showed weekly formulation of setmelanotide trough drug concentration similar to daily formulation –

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which

SubioMed, Inc. (“SubioMed™” or the “Company”), a pioneer in the invention and development of disruptive Suspension Biomechanics™ technology addressing critical elements of gait and balance, today announced that it has successfully completed its initial equity financing round of $1.5M. The common stock offering saw insider participation, in addition to investments from individual angel investors. Patrick Kullmann, Chairman and Chief Executi

Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumab’s use with viral infections, including COVID-19. Dr. Singh stated, “With the present pandemic, the need for further research is essential to both understand and inhibit COVID-19’s continual spread. This opportunity with Nascent Biotech allows me to continue my medical work in viral infectio

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, today announced that it has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OH

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has again affirmed its strategic commitment to leadership in cybersecurity risk management and cybersecurity protection by partnering with Clearwater, the leading provider of enterprise cyber risk management solutions for the healthcare industry.

Docbot, Inc., a privately-held company developing leading artificial intelligence (AI)-driven healthcare applications, today announced the first subjects enrolled at Gastro Health in a pivotal trial to validate Ultivision™ AI imaging platform for adenoma detection during colonoscopy screenings.

Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy , Ph.D., president and CEO, plans to present an overview of the company and update on their clinical development

Return Ready™ offers organizations a customizable COVID-19 testing solution, clinical protocols and reporting to meet their unique worksite or campus needs